Press releases


INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020

Oxford, UK – 17 September 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR), a leading medical device business focused on respiratory disease, today announces its unaudited interim results for the six months ended 30 June 2020. Financial highlights

CIRCASSIA GROUP PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019

Oxford, UK – 16 June 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR) today announces its preliminary results for the year ended 31 December 2019 and a post-period update. Financial progress Key performance indicators £m 2019 underlying continuing

Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest

The information contained within this announcement is deemed by Circassia Pharmaceuticals plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information

Circassia Announces Business Update

Oxford, UK – 9 January 2020: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces a business update including a trading update for the year ended 31 December 2019. Unaudited

Update on Circassia’s Licensing Agreement with BeyondAir Inc. for LungFit PH

Oxford, UK – 19 December 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, provides an update on its licensing agreement with BeyondAir Inc. (previously AIT Therapeutics Inc.) for the commercial

Circassia Announces Board Changes

Oxford, UK – 5 December 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces a number of changes to its Board and Executive Management. Chief Executive Officer Circassia announces

Circassia Announces Duaklir® US Launch at American College of Chest Physicians’ CHEST Annual Meeting 2019

– Duaklir® launch expands Circassia’s US portfolio of COPD products alongside Tudorza® – Oxford, UK and Morrisville, NC, United States – 21 October 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory

Interim results for the six months ended 30 June 2019

Oxford, UK – 26 September 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its unaudited interim results for the six months ended 30 June 2019 and a post-period

Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer

– COO to join Board and SVP R&D to step down as Director reflecting Company’s commercial focus – Oxford, UK – 12 August 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory

Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association

Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of

Preliminary Results for the Year Ended 31 December 2018

Oxford, UK – 1 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its preliminary results for the year ended 31 December 2018 and a post-period update. Financial

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

– Duaklir® launch planned H2 2019 – – Duaklir® to join Tudorza® in Circassia’s portfolio of US COPD products – Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused

Circassia Announces FDA Approval of Tudorza® Supplemental New Drug Application

This announcement contains inside information for purposes of Article 7 of Market Abuse Regulation 596/2014 Click here to download the full press release – Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added

Admission to AIM

Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR),a specialty pharmaceutical company focused on respiratory disease, today announces that further tothe Company’s announcement on 10 December 2018 and the General Meeting on 4 January

Admission to trading on the London Stock Exchange

NOT INTENDED TO PROMOTE THE SALE OF ANY SECURITIES, AND NOT FOR PUBLICATION,DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTOTHE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THEUNITED STATES AND THE